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that offers clients a wide range of pharmaceutical research 
services to aid in the drug and medical device research and 
development process.[1,2] In the Code of Federal Regulations 
(CFR), the USFDA regulations state that a CRO is “a 
person (i.e. a legal person, which may be a corporation) that 
assumes, as an independent contractor with the sponsor, 
one or more of the obligations of a sponsor, e.g., design 
of a protocol, selection or monitoring of investigations, 
evaluation of reports, and preparation of materials to be 
submitted to the Food and Drug Administration” [21 CFR 
312.3(b)].[2]  Although a set of guidelines that governs the 
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ABSTRACT
A contract research organization (CRO) is a company which conducts a Good Clinical Practice (GCP) in clinical 
trial. There are literally hundreds of CROs worldwide employing a workforce of nearly 100,000 professionals. 
The project proposes the study of practical parameters and their relative importance as perceived by the various 
stakeholders in clinical trials. The survey was conducted in Bangalore and New Delhi. Primary market data 
was obtained by primary market research which included 80 clinical trial stakeholders by having a preliminary 
communication with them, followed by administering a questionnaire along with prior permission. There were 
15 Sponsors/ CROs, 27 Investigators /Monitors and 38 Ethics committee members involved in the study. It was 
shown from the study that a clinical investigator involved in a clinical trial is responsible for ensuring that an 
investigation is conducted according to the signed investigator statement, the investigational plan, and applicable 
regulations; for protecting the rights, safety, and welfare of the subjects under the investigator’s care; and for 
the control of drugs under investigation. It was also shown from the study that the sponsors of a clinical trial 
carry the ultimate responsibility for the initiation, management and financing of the clinical trial. The study has 
identified a specific training need at the level of the individual stakeholder to perform a particular job function 
and to identify the actual practical parameters in the Indian context important for the conduction of clinical trials 
(GCP) with respect to the different stakeholders, to determine the relative importance of these parameters as 
perceived by various stakeholders involved in clinical trials, and to identify the relative contributions of different 
stakeholders to the success/ satisfactory conduct of a clinical trial.
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conduct of clinical trials in any country is available nowhere 
is any data available that talks about the motivators/
demotivators to various stakeholders (investigators/ 
sponsors/ ethics committee members etc.) for conducting 
a clinical trial.[3] This aspect is especially important for India 
as more and more number of studies are being undertaken 
in India and the clinical research profession is expected 
to boom. The foreign pharmaceutical companies and 
CROs are expanding their base to India and conducting 
a lot of clinical studies, however, none of them try to 
address the actual practical parameters that are of relative 
importance to Indian investigators, such as relevance of 
the study to the Indian population, publication policy, trial 
management capabilities, benefit to study participants, 
communication skills, grants and payments, etc.[4] Thus 
the study is not only an attempt to identify the practical 
parameters of importance for the conduct of GCP clinical 
trials but also to identify their relative importance in the 
mind of various stakeholders (investigators/ sponsors/ 
ethics committee members etc.). As a result it will further 
support the clinical research industry in India by providing 
the level of importance for the individual parameter. The 
main objectives of this study were to identify the actual 
practical parameters in the Indian context important for 
the conduction of clinical trials (GCP) with respect to the 
different stakeholders, to determine the relative importance 
of these parameters as perceived by various stakeholders 
involved in clinical trials and also to identify the relative 
contributions of different stakeholders to the success/ 
satisfactory conduct of a clinical trial.
METHODOLOGY
Source of data
The sources for market research involve both primary 
and secondary sources. Primary sources include Ethics 
Committee Members (ECMs), Investigators and Sponsors 
while secondary sources involve the use of Internet, 
Textbooks and Journals (Such as Pharma pulse, Pharma 
biz etc).
Methods of data collection
Preliminary communication with various clinical research 
professionals/stakeholders; followed by administering a 
questionnaire.
Place and time of survey
The survey was conducted in Bangalore and New Delhi 
from January to June 2007.
Sample size
1.  Total sample size - 80
2.  Sponsors / CROs - 15
3.  Investigators / Monitor - 27
4.  Ethics committee members (ECMs) - 38
Sampling technique- Convenience sampling
Data analysis method- The data obtained was analyzed using 
Microsoft Excel and various observations were analyzed 
to arrive at the conclusion.
RESULTS
I.  Parameters to conduct GCP clinical trial according 
to the ECMs’ opinion [Figure 1]:
1.  100.0% mentioned scientific rationale of the 
study 
2.  98.9% opined protection of rights and safety 
of the trial participants 
3.  93.9% stated about the clearance of the study 
project from Drugs Controller General of India 
(DCGI) 
4.  92.8% referred to investigator’s qualification and 
clinical research experience
5.  91.1% mentioned quality of protocol, case 
report form (CRF) and informed consent 
document (ICD) design  
6.  88.9% declared compensation clause for trial-
related injuries 
7.  82.8% stated about the clearance of project 
from foreign regulatory authorities  
8.  81.1% mentioned investigator’s grants and 
payment  
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9.  74.4% referred to the involvement of investigator 
site in the multi-countries project
II.  Parameters for the role of the ethics committee in 
clinical triasl according to the ECMs’ opinion: 
1.  100.0% mentioned safeguarding the right, safety, 
and wellbeing of all trial subjects  
2.  92.2% stated that a competent review of all 
ethical aspects of the project proposals received 
must be ensured 
3.  91.8% declared that the project be executed free 
from any bias and influence that could affect its 
objectivity  
4.  90.2% opined that universal ethical values and 
international scientific standards should be 
expressed in terms of local community values 
and customs
III.  Principles to conduct GCP clinical trial according to 
the ECMs’ opinion: 
1.  100.0% opined principles of compliance  
2.  95.6% mentioned principles of privacy and 
confidentiality  
3.  94.5% stated principles of voluntariness, 
informed consent and community agreement
4.  92.9% declared principles of essentiality, and 
principles of totality of responsibility   
IV.  Parameters of study design to conduct GCP 
clinical trial according to the Investigators’ opinion   
[Figure 2]:
1.  100.0% mentioned scientific rationale of the 
study 
2.  96.0% stated application of the study in the 
Indian context 
3.  87.9% opined benefit to study participants  
4.  84.7% declared publication policy  
V.  Parameters of project management (Sponsor/
CRO) to conduct GCP clinical trial according to the 
Investigators’ opinion:
1.  100.0% opined scientific quality of protocol, 
CRF and ICD design 
2.  96.6% mentioned trial logistics (centralized lab, 
imaging and data management facility) 
3.  94.1% stated study grant 
4.  93.3% declared inventory planning and 
management for study supplies  
VI.  Parameters of personnel quality to conduct GCP 
clinical trial according to the Investigators’ opinion   
[Figure 3]:
1.  100.0% mentioned trial management capabilities 
2.  96.8% declared qualification and experience 
3.  96.0% opined communication skills 
4.  89.5% stated responsiveness 
VII.  Parameters for Investigator capabilities and experience 
to conduct GCP clinical trial according to the 
Sponsors’ opinion [Figure 4]:  
1.  100.0% mentioned commitment/involvement 
of principal investigator (PI) in the study
2.  95.5% opined about clinical trial experience of 
the investigator 
3.  94.0% stated availability of desired patient 
population 
4.  92.5% referred to availability of GCP-trained 
study coordinator 
5.  79.1% declared leader stature of the investigator 
in the desired therapeutic area 
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VIII. Parameters for facility available at trial site to conduct 
GCP clinical trial according to the Sponsors’ opinion:
1.  100.0% mentioned quality control (QC) /quality 
assurance (QA) procedure of the lab 
2.  95.5% stated Ethics Committee’s Standard 
Operating  Procedure  (EC’s  SOP)  in 
compliance with International Conference on 
Harmonisation-Good Clinical Practice (ICH-
GCP) and applicable regulatory guidelines and 
availability of dedicated space for drug storage, 
record-keeping and monitoring  
3.  94.0% opined about post-study archival facility 
IX.  Parameters related to clinical trial conduct according 
to the Sponsors’ opinion:
1.  100.0% mentioned protocol adherence and 
GCP compliance 
2.  92.5% stated meeting enrolment, and data 
management matrix  
3.  79.1% declared cost-effectiveness 
X.  Importance of CROs in conducting clinical trials 
according to the Sponsors’ opinion:
1.  100.0% mentioned that CROs provide rapid, 
flexible access to additional research and 
development capacity/resources, product of 
outside sponsor’s core therapy areas and product 
at high risk
2.  98.4% stated risk management tool for high-risk, 
low-priority projects, CROs have better access 
to patients
3.  96.9% opined about sponsors transfer fixed 
costs to variable costs and access to enabling 
technology 
4.  95.3% mentioned access to therapeutic expertise 
outside core areas 
DISCUSSION
According to the ECMs surveyed, the majority mentioned 
that scientific rationale of the study, protection of the rights 
and safety of the trial participants, clearance of the study 
project by DCGI, investigator’s qualification and clinical 
research experience are the most important parameters to 
conduct GCP clinical trials. They mentioned that their most 
important role in the clinical trial is to safeguard the right, 
safety, and wellbeing of all trial subjects and also to ensure 
a competent review of all the ethical aspects of the project 
proposals received as well as to execute the project free 
from any bias and influence that could affect its objectivity. 
ECMs stated that they follow all the principles while 
reviewing the clinical trial protocols. According to them the 
most important are principles of compliance, principles of 
privacy and confidentiality, and principles of voluntariness, 
informed consent and community agreement. 
According to the investigators surveyed, they mentioned 
various parameters to conduct GCP clinical trial. They 
said that scientific rationale of the study and application 
of the study in the Indian context are the most important 
parameters of study design for conducting GCP clinical 
trial. Furthermore, they stated that scientific quality of 
protocol, CRF and ICD design are the most important 
parameters of project management (Sponsor/CRO).   
Finally, they opined that trial management capabilities, 
qualification and experience, communication skills and 
responsiveness are very important parameters of personnel 
quality (Clinical Research Associate or CRA/Monitor) for 
conducting GCP clinical trial. 
The sponsor may be an individual, company, institution, or 
organization which takes responsibility for the initiation, 
management, and/or financing of a clinical trial. An 
individual who both initiates and conducts, alone or with 
others, a clinical trial, and under whose immediate direction 
the investigational product is administered to, dispensed to, 
or used by a subject. According to the sponsors surveyed, 
they mentioned that the commitment/involvement of the 
principal investigator (PI) in the study is most important for 
investigator’s capabilities and experience. In continuation 
of the detailed discussion, they stated that quality control/
quality assurance procedure of the lab, protocol adherence 
and GCP compliance, rapid and flexible access to additional 
research and development capacity/resources, product of 
outside sponsor’s core therapy areas and product at high 
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risk are the most important parameters for conducting 
GCP clinical trial. 
CONCLUSION
The study has identified a specific training need at the 
level of the individual stakeholder to perform a particular 
job function and the key objectives of the study are as 
follows: to identify the actual practical parameters in the 
Indian context important for the conduction of clinical 
trials (GCP) with respect to the different stakeholders, to 
determine the relative importance of these parameters 
as perceived by various stakeholders involved in clinical 
trials, and to identify the relative contributions of different 
stakeholders to the success/ satisfactory conduct of a 
clinical trial.
According to the stakeholders surveyed, the scientific 
rationale of the study, safeguarding the right, safety, and 
wellbeing of all trial subjects, principles of compliance, 
quality  of   protocol,  CRF  and  ICD  design,  trial 
management capabilities, qualification and experience, 
and communication skills of personnel (CRA/Monitor), 
commitment/ involvement of principal investigator (PI) 
in the study, QC/QA procedure of the lab, protocol 
adherence and GCP compliance are the most important 
practical parameters which would contribute to the 
successful conduct of a GCP clinical trial.
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